



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Edwards

Phone: 650-351-4730

E-mail:

investor@globalbloodtx.com

Stock Performance

GBT (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$29.85**

Change (%) ▲ 0.60 (2.05%)

Volume 3,199,127

52 Week Low \$13.35

Market Cap \$1,301,854,348

Rolling EPS -2.50

PE Ratio 0

Shares Outstanding 43,613,211

Data as of 06/23/17 4:00 p.m. ET



Recent Headlines & Events

06/23/17

[Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease](#)

06/06/17

[Global Blood Therapeutics Announces Participation at the Goldman Sachs 38th Annual Global Healthcare Conference](#)

05/18/17

[Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association's 22nd Congress](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/23/17	<u>8-K</u>
06/22/17	<u>4</u>
06/22/17	<u>4</u>
06/22/17	<u>4</u>

Corporate Governance

<u>Ted W. Love, M.D.</u>	Chief Executive Officer
<u>Jeffrey Farrow</u>	Chief Financial Officer
<u>Jung E. Choi</u>	Chief Business and Strategy Officer
<u>Tricia Suvari</u>	Chief Legal Officer
<u>Hing Sham, Ph.D.</u>	Senior Vice President, Research
<u>Peter Radovich</u>	Vice President, Program Leadership and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.